| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 16,150 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -77,330 | -73,790 | -120,720 | -75,980 | -12,830 |
| Net Income Growth | -4.80% | +38.88% | -58.88% | -492.21% | unch |
Pyxis Oncology Inc (PYXS)
0.9801 x 3 1.0000 x 2
Pre-market by (Cboe BZX)
0.9799 -0.0801 (-7.56%) 03/31/25 [NASDAQ]
0.9801 x 3 1.0000 x 2
Pre-market 0.9801 +0.0002 (+0.02%) 08:00 ET
for Mon, Mar 31st, 2025
Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.
Fiscal Year End Date: 12/31